|
KMID : 0370220160600040163
|
|
Yakhak Hoeji
2016 Volume.60 No. 4 p.163 ~ p.172
|
|
|
Trends of State of the Art Technologies on New Drug Development using Accelerator Mass Spectrometry
|
|
Shin Seok-Ho
Park Min-Ho
Hwang Ye-Ran
La Soo-Kie
Lee Hee-Joo
Dueker Stephen R.
Shin Young-Geun
|
|
|
Abstract
|
|
|
|
The pharmaceutical is continuously seeking out new tools to bring efficiency and price control to the overall cost of drug development. It is well known that a large percentage of the integrated cost of developing a single drug is the cost of the failed compounds in clinical development. Thus, any tool that brings efficiency to early clinical development is of high value. Radiolabeled molecules are excellent investigative tools that enable absolute quantification in any biological matrix with minimal method development. For in vivo studies, radiolabeled compounds are employed to identify and elucidate metabolites, define routes and rates of excretion, assess bioavailability and even understand target tissue and receptor exposure. These studies are most valuable when performed early in clinical development. Accelerator Mass Spectrometry (AMS) brings high sensitivity and precision to the measurement of radiocarbon (14C), reducing clinical radiative exposure to harmless small levels that can be treated as non-radioactive. As a result, many new avenues of clinical investigation are virtually possible and probable in volunteer or patient populations. Earlier forms of AMS were not customized for bioanalysis, but the situation is changing with recent advances in the technology. We review important areas of applied AMS for micro-dosing and micro-tracing and discuss the latest development in radiocarbon detection by AMS and new laser based systems.
|
|
|
KEYWORD
|
|
|
accelerator mass spectrometry, pediatrics, biotherapeutics, automated AMS, LC-AMS
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|